Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436) — Capital Reinvestment Ratio
Zhangzhou Pientzehuang Pharmaceutical Co Ltd (600436) has a Capital Reinvestment Ratio of 0.48x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥117.38 Million) in capital expenditures (CN¥56.87 Million). Check 600436 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Zhangzhou Pientzehuang Pharmaceutical Co Ltd Capital Reinvestment Ratio (2001–2025)
This chart tracks Zhangzhou Pientzehuang Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 24 annual periods. For the full cash flow conversion analysis, see Zhangzhou Pientzehuang Pharmaceutical Co (600436) cash conversion ratio.
Annual Capital Reinvestment Ratio for Zhangzhou Pientzehuang Pharmaceutical Co Ltd (2001–2025)
Year-by-year Capital Reinvestment Ratio for Zhangzhou Pientzehuang Pharmaceutical Co Ltd from 2001 to 2025. See 600436 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 4.41x | CN¥77.03 Million | CN¥339.80 Million | ▲ +442.5% |
| 2024 | 0.81x | CN¥1.31 Billion | CN¥1.07 Billion | ▲ +1164.8% |
| 2023 | 0.06x | CN¥2.21 Billion | CN¥141.87 Million | ▲ +152.0% |
| 2022 | 0.03x | CN¥6.87 Billion | CN¥175.37 Million | ▼ -87.2% |
| 2021 | 0.20x | CN¥462.27 Million | CN¥92.17 Million | ▼ -30.2% |
| 2020 | 0.29x | CN¥1.47 Billion | CN¥419.01 Million | ▲ +135.6% |
| 2018 | 0.12x | CN¥612.31 Million | CN¥74.24 Million | ▲ +58.2% |
| 2017 | 0.08x | CN¥676.93 Million | CN¥51.87 Million | ▼ -66.8% |
| 2016 | 0.23x | CN¥394.54 Million | CN¥90.97 Million | ▼ -10.7% |
| 2015 | 0.26x | CN¥305.51 Million | CN¥78.86 Million | ▲ +164.0% |
| 2014 | 0.10x | CN¥264.50 Million | CN¥25.87 Million | ▼ -81.7% |
| 2013 | 0.53x | CN¥274.34 Million | CN¥146.54 Million | ▼ -44.1% |
| 2012 | 0.96x | CN¥162.40 Million | CN¥155.22 Million | ▲ +526.1% |
| 2011 | 0.15x | CN¥232.95 Million | CN¥35.56 Million | ▼ -19.4% |
| 2010 | 0.19x | CN¥205.41 Million | CN¥38.90 Million | ▼ -17.3% |
| 2009 | 0.23x | CN¥129.52 Million | CN¥29.67 Million | ▼ -95.1% |
| 2008 | 4.65x | CN¥12.57 Million | CN¥58.50 Million | ▲ +162.4% |
| 2007 | 1.77x | CN¥60.04 Million | CN¥106.47 Million | ▲ +932.2% |
| 2006 | 0.17x | CN¥50.70 Million | CN¥8.71 Million | ▼ -65.6% |
| 2005 | 0.50x | CN¥69.06 Million | CN¥34.54 Million | ▲ +358.9% |
| 2004 | 0.11x | CN¥98.67 Million | CN¥10.75 Million | ▼ -77.3% |
| 2003 | 0.48x | CN¥32.36 Million | CN¥15.56 Million | ▲ +419.2% |
| 2002 | 0.09x | CN¥105.45 Million | CN¥9.77 Million | ▼ -47.6% |
| 2001 | 0.18x | CN¥65.84 Million | CN¥11.64 Million | — |